FAQs | How to Order | Contact Us | Prescribing Information | Important Safety Information
 Register  |  Login

Multimedia Training Presentation
Meridian Medical Technologies, a subsidiary of King Pharmaceuticals®, Inc., has developed a multimedia training presentation to train colleagues, conduct inservice programs, or familiarize managers with the importance of being prepared with DuoDote™ Auto-Injector. This presentation, titled "Guidelines and Injection Instructions for DuoDote Auto-Injector," is available to registered users in either PowerPoint or Adobe Acrobat PDF formats.

Registration is quick, easy, and free. Please click here to log in or register and download your copy of this helpful training presentation.


Additional Training Resources
Registered users of DuoDote.com will receive E-mail updates when additional training resources become available, such as materials from academic research centers including video presentations (downloadable from this Web site or shipped to you on DVD). You can also request training materials by contacting a Meridian account representative at 1.800.638.8093 or by sending an E-mail to info@meridianmt.com.

The DuoDote™ Auto-Injector (atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL) is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides.

IMPORTANT SAFETY INFORMATION

The DuoDote Auto-Injector is intended as an initial treatment of the symptoms of organophosphorus insecticide or nerve agent poisonings; definitive medical care should be sought immediately. The DuoDote Auto-Injector should be administered by Emergency Medical Services personnel who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication.

Individuals should not rely solely upon agents such as atropine and pralidoxime to provide complete protection from chemical nerve agents and insecticide poisoning. Primary protection against exposure to chemical nerve agents and insecticide poisoning is the wearing of protective garments including masks designed specifically for this use. Evacuation and decontamination procedures should be undertaken as soon as possible. Medical Personnel assisting evacuated victims of nerve agent poisoning should avoid contaminating themselves by exposure to the victim's clothing.

In the presence of life-threatening poisoning by organophosphorus nerve agents or insecticides, there are no absolute contraindications to the use of the DuoDote Auto-Injector. When symptoms of poisoning are not severe, DuoDote Auto-Injector should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial infarction, severe narrow angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal insufficiency, chronic pulmonary disease, or hypersensitivity to any component of the product.

Please click here to view full prescribing information for DuoDote.

Site Map | References | Copyright | Privacy Policy | Terms of Use | About Meridian


© 2007 Meridian Medical Technologies™ Inc., a subsidiary of King Pharmaceuticals®, Inc. DuoDote™ Auto-Injector, the DuoDote logo, BinaJect™, and Mark I™ Kit are trademarks of Meridian Medical Technologies™, Inc. AtroPen® is a registered trademark of Meridian Medical Technologies™, Inc. MMT 4908 10/07®